← Eichor
Study identifier: NCT02938611 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Feasibility of Estimating the Prevalence and Management of Stage 4 CKD the Gard, France

Condition: Renal Insufficiency, Chronic  ·  Sponsor: Centre Hospitalier Universitaire de Nīmes

PhaseN/A
Planned participants3375
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

The main objective of this study is to evaluate the feasibility of estimating the prevalence of stage 4 and 5 chronic kidney disease in the Gard department of France from data obtained via laboratory databases. To verifiy if the demand for care thus authenticated by laboratory tests is adapted to nephrology care delivery, as recommended by the French High Authority of Health (HAS), laboratory data will be compared with those of patients seen by nephrologists in the department.

This description comes directly from the study's public registry record.

Talk to the study team

Olivier Moranne, MD, PhD  ·  +33.(0)4.66.68.31.49  ·  olivier.moranne@chu-nimes.fr

Always discuss trial participation with your own doctor first.

Locations (4)

AIDER - Unité de Dialyse d'AlèsAlès, FranceRecruiting
AIDER - Unité de Dialyse de Nîmes, CHU CarémeauNîmes, FranceNot Yet Recruiting
CHU de Nîmes - Hôpital Universitaire CarémeauNîmes, FranceNot Yet Recruiting
GardialyseNîmes, FranceNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02938611